A Satisfying Sex Life Eludes Around Two In Three Men Pfizer's inaugural Asia Pacific Sexual Health and Overall Wellness (AP SHOW) survey has uncovered staggering levels of sexual dissatisfaction, with 60% of men and around 60% of women in Australia saying they are not very satisfied with their sex lives. Erectile Dysfunction (ED) continues to be a key cause of dissatisfaction.
Source: www.medicalnewstoday.comCHEST 2008: New Pulmonary Hypertension Research Presented #6363 TADALAFIL PROVES EFFECTIVE THERAPY FOR PULMONARY HYPERTENSION New research shows that the erectile dysfunction drug, tadalafil, may be an effective adjunct therapy for patients with pulmonary arterial hypertension (PAH). Italian researchers randomized 405 patients with PAH, of whom 53 percent were taking concomitant bosentan, to two study arms. The groups received either tadalafil or placebo orally once daily as monotherapy or as add-on therapy to bosentan.
Source: www.medicalnewstoday.comEvaluation Of The Safety And Efficacy Of Sildenafil Citrate For Erectile Dysfunction In Men With Multiple Sclerosis UroToday.com - The etiology of multiple sclerosis (MS)-emergent erectile dysfunction (ED) is still matter of debate, since both organic and psychological factors have been implicated. There is an association between sexual dysfunction (SD) and destructive lesions in the pons, in MS patients. Central and peripheral nerves systems play a key role in the erectile process. The innervation of the penis is both autonomic (sympathetic and parasympathetic) and somatic (sensory and motor).
Source: www.medicalnewstoday.comRexahn Completes Patient Enrollment In Phase IIa Clinical Trial Of ZoraxelTM To Treat Erectile Dysfunction Rexahn Pharmaceuticals, Inc. (NYSE Alternext US: RNN), a leader in development of innovative therapeutics for life-threatening and life-debilitating diseases, announced the completion of enrollment in its Phase IIa clinical trial evaluating ZoraxelTM for treatment of Erectile Dysfunction (ED). The Company expects to have preliminary study results in March 2009.
Source: www.medicalnewstoday.comSenators Introduce Legislation To End Agreements Between Brand-Name, Generic Pharmaceutical Companies Sens. Herb Kohl (D-Wis.) and Chuck Grassley (R-Iowa) on Tuesday announced that they have introduced a bill (S 369) to end agreements under which brand-name pharmaceutical companies pay generic pharmaceutical companies to delay the launch of generic versions of the medications, CQ HealthBeat reports.
Source: www.medicalnewstoday.comAvoiding Incorrect Dosing Of A Common Drug Using Genetic Profiles Your DNA affects your hair color, your blood type and even how you react to some medications. Now scientists have taken a big step toward folding your personal genetic profile into many of the prescriptions you carry away from the
pharmacy. Most immediately, the advance will likely lead to the safer, more effective use of a common anticoagulant called warfarin that, when taken in the wrong amount, can be very dangerous.
Source: www.medicalnewstoday.comUSA's Largest Ever Prostate Cancer Screening Programme Shows High Compliance And Consistent Results Just under five per cent of the men who took part in the prostate cancer element of the USA's largest ever cancer screening trial were diagnosed with the disease and the majority of those were picked up by screening programmes, according to research published in the December issue of the UK-based urology journal BJU International.
Source: www.medicalnewstoday.com
# posted by Network @ 10:15 PM
